1.Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
Noriko NISHIKAWA ; Taku HATANO ; Daiki KAMIYAMA ; Haruna HAGINIWA-HASEGAWA ; Genko OYAMA ; Nobutaka HATTORI
Journal of Movement Disorders 2022;15(3):290-292
2.Phenotypic diversity of hereditary sensory and autonomic neuropathy type IE: a case series and review of the literature
Noriyuki Miyaue ; Yuki Yamanishi ; Satoshi Tada ; Rina Ando ; Hayato Yabe ; Noriko Nishikawa ; Masahiro Nagai ; Hiroshi Takashima ; Masahiro Nomoto
Neurology Asia 2019;24(1):15-20
Objective: DNA methyltransferase 1 (DNMT1) is crucial to maintaining methylation during DNA
replication and DNA repair. DNMT1 mutations have been identified in two neurological syndromes,
including hereditary sensory and autonomic neuropathy type IE (HSAN IE) with dementia and
hearing loss and autosomal dominant cerebellar ataxia, deafness and narcolepsy. It is likely that
DNMT1 mutations lead to various symptoms of the central and peripheral nervous system. The aim
of this study was to examine the clinical characteristics, especially the initial symptoms, in the cases
of DNMT1 mutations. Methods: We investigated the clinical manifestation and examination findings
of four cases of HSAN IE from one family with the DNMT1 mutation c.1531Y>C (p.Try511His).
Results: All four cases exhibited sensory neuropathy, cerebellar ataxia, and hearing loss, all of which
were demonstrated by the audiograms. The initial symptoms of the four cases included hearing loss
(n=1), gait disturbance (n=1), and depressive mood (n=2). Depressive symptoms are reported in some
cases with HSAN IE, however, there are currently no published reports that describe them as primary
symptoms. The CSF orexin level was measured in three cases, revealing normal values in two cases
and intermediate values in one case, in which the patient exhibited rapid eye movement (REM) sleep
behavior disorder.
Conclusion: Our findings suggest that in cases with HSAN IE or the DNMT1 mutation, psychiatric
symptoms should be taken into account as one of the initial manifestations of the disease.